In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Shaping The Medical Industry, October 2014

Executive Summary

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August-September 2014.

You may also be interested in...



RenalGuard Gets Capital Infusion To Push AKI-Prevention Device Into US

RenalGuard Solutions has attracted $14.5m from investors and will use the funds to take its novel device, designed to prevent acute kidney injury following cardiac interventional procedures, into the US.

Ways To Find And Nurture Young, Diverse Talent In Pharma

On this podcast, In Vivo's Jo Shorthouse is joined by Rebekah Martin, senior vice president of reward, inclusion, and talent acquisition at AstraZeneca to talk about the ways that pharma should be encouraging a diverse and inclusive team of young talent, and that strong connection between diversity of thought and innovation.

Snapshot: September Highlights

A selection of articles you might have missed from September 2022, including highlights from In Vivo's spotlight on rare diseases, their diagnosis and treatment.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV004287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel